Ernexa director granted options on 5,083 shares

Subject to continued service, David Polinsky’s 5,083 option grant from ERNA vests 100% on Dec. 31, 2026.

Rhea-AI Filing Summary

Ernexa Therapeutics Inc. (ERNA) reported that director David Polinsky received a grant of stock options covering 5,083 shares of common stock. The options have an exercise price of $4.57 per share, were granted in lieu of prorated director cash compensation for 2026 under the company’s 2026 Omnibus Equity Incentive Plan, and expire on August 31, 2036. Subject to continued service, 100% of the options vest on December 31, 2026, and Polinsky’s total holdings of this option grant are 5,083 options following the reported transaction.

Insider Trade Summary

Grant/Award: 5,083 shares

Grant/Award 1 txn

Insider Polinsky David

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy) F1	5,083	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to buy) — 5,083 contracts (Direct)

Footnotes (1)

1. F1. Represents options to purchase shares of the registrant's common stock in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan effective August 15, 2026, granted under the Issuer's 2026 Omnibus Equity Incentive Plan. Subject to continued service, 100% of the stock options will vest on December 31, 2026.

Key Figures

Stock options granted: 5,083 options Exercise price: $4.57 per share Transaction price per share: $0.00 per option +3 more

6 metrics

Stock options granted 5,083 options Number of stock options granted to director David Polinsky on 2026-08-31

Exercise price $4.57 per share Conversion or exercise price for the stock options granted on 2026-08-31

Transaction price per share $0.00 per option Indicates the options were granted at no cost as compensation

Underlying common shares 5,083 shares Common stock underlying the stock options granted to David Polinsky

Vesting date December 31, 2026 Date when 100% of the options vest, subject to continued service

Expiration date August 31, 2036 Expiration date of the stock options granted

Key Terms

Stock Option, Director's Compensation Plan, Omnibus Equity Incentive Plan, vest

4 terms

Stock Option financial

"Represents options to purchase shares of the registrant's common stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Director's Compensation Plan financial

"in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan"

Omnibus Equity Incentive Plan financial

"granted under the Issuer's 2026 Omnibus Equity Incentive Plan"

A single, company-wide plan that lets a business grant different kinds of stock-based pay — such as stock options, shares that vest over time, or other equity awards — to employees, directors and consultants. It matters to investors because it determines how much of the company can be paid out in shares, how quickly those shares enter the market, and how well employees are motivated to grow the business; think of it as a toolbox or menu for paying with ownership stakes that can dilute existing holders and affect company performance.

vest financial

"Subject to continued service, 100% of the stock options will vest on December 31, 2026"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ERNA director David Polinsky report on this Form 4?

David Polinsky reported an option grant for 5,083 shares of Ernexa Therapeutics Inc. common stock. The options were granted as compensation in stock options instead of prorated director cash compensation for 2026, under the company’s 2026 Omnibus Equity Incentive Plan.

What is the exercise price of the stock options granted to David Polinsky at ERNA?

The stock options granted to David Polinsky have an exercise (conversion) price of $4.57 per share. This is the price at which he may purchase Ernexa Therapeutics Inc. common shares upon exercising the options.

When do David Polinsky’s ERNA stock options vest and expire?

Subject to continued service, 100% of the stock options vest on December 31, 2026. The options have an expiration date of August 31, 2036, after which any unexercised options will lapse.

How many ERNA options does David Polinsky hold after this reported transaction?

After this reported transaction, David Polinsky holds 5,083 stock options covering 5,083 shares of Ernexa Therapeutics Inc. common stock related to this grant, as indicated by the total shares following the transaction field.

Was the ERNA option grant to David Polinsky part of a cashless or paid transaction?

The Form 4 reports a transaction price per share of $0.00 for the grant, meaning the options were awarded as compensation rather than purchased for cash. The $4.57 figure is the exercise price payable if and when the options are exercised.

Is the ERNA option grant to David Polinsky under a specific compensation plan?

Yes. The options were granted in lieu of prorated director’s cash compensation for 2026 pursuant to the Director’s Compensation Plan effective August 15, 2026, and were granted under Ernexa Therapeutics Inc.’s 2026 Omnibus Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 09:49 PM EDT Accepted by SEC EDGAR 09/01/2026 - 09:49 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Polinsky David

(Last) (First) (Middle)

C/O ERNEXA THERAPEUTICS INC.

1035 CAMBRIDGE STREET, SUITE 18A

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ernexa Therapeutics Inc. [ ERNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$4.57	08/31/2026		A		5,083		(1)	08/31/2036	Common Stock	5,083	$0(1)	5,083	D

Explanation of Responses:

1. Represents options to purchase shares of the registrant's common stock in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan effective August 15, 2026, granted under the Issuer's 2026 Omnibus Equity Incentive Plan. Subject to continued service, 100% of the stock options will vest on December 31, 2026.

	/s/ David Polinsky	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)